Merck & Co. Revives Ophthalmology Efforts with $3 Billion EyeBio Acquisition ###

###
1. Merck & Co. Acquires EyeBio: Merck & Co. has announced a deal worth $3 billion to acquire EyeBio, marking its return to the ophthalmology space after nearly a decade.
2. EyeBio's Trispecific Antibody: EyeBio's first-in-class trispecific antibody, Restoret, is part of the acquisition, which could significantly enhance Merck's ophthalmology portfolio.
3. Ophthalmology Market: The acquisition signals Merck's renewed focus on ophthalmology, a market with growing demand and potential for significant growth.
4. Biotech Industry Trends: The deal is part of a larger trend in the biotech industry, where companies are shifting investment strategies and prioritizing larger, more stable investments.
5. Market Expectations: The acquisition is expected to have a significant impact on the ophthalmology market, with analysts projecting continued growth in the sector.